T14.SI - Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

SES - SES Delayed Price. Currency in USD
Show:
Balance sheet
Cash flow
Annual

Income statement

Currency in CNY. All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
7,118,333
8,249,250
6,907,544
6,603,652
6,993,882
Cost of revenue
4,330,775
4,955,592
4,150,424
4,027,755
4,046,928
Gross profit
2,787,558
3,293,658
2,757,120
2,575,897
2,946,953
Operating expenses
Research development
158,846
153,147
161,052
149,202
133,361
Selling general and administrative
1,637,620
2,049,442
1,645,040
1,541,679
1,914,801
Total operating expenses
2,138,873
2,570,316
2,143,941
1,979,962
2,380,869
Operating income or loss
648,685
723,342
613,179
595,934
566,084
Interest expense
3,833
10,269
2,937
6.66
4,893
Income before tax
956,810
980,188
872,806
768,058
743,145
Income tax expense
100,725
106,931
85,929
88,396
107,786
Income from continuing operations
856,086
873,258
786,877
679,662
635,359
Net income
836,594
861,794
769,144
661,704
625,569
Net income available to common shareholders
836,594
861,794
769,144
661,704
625,569
Basic EPS
-
-
1.00
0.86
0.81
Diluted EPS
-
-
1.00
0.86
0.81
Basic average shares
-
-
769,144
769,424
772,307
Diluted average shares
-
-
769,144
769,424
772,307
EBITDA
-
1,107,016
991,277
878,913
846,187